Biosyent Inc. · TSXV:RX
Biosyent — Q1 2023 Earnings Presentation
14 slides from Biosyent's earnings presentation, May 26, 2023
Slide 1: BioSyent Inc. Q1 2023 Results
BioSyent Inc. Q1 2023 Results MAY 26, 2023 PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: Q1 2023 Sales Summary ($)
Q1 2023 Sales Summary ($) Q1 ‘23 Q1 ‘23 vs. Canadian Pharma Sales ($) Q1 ’22 (%) Strong end market demand growth (sales by wholesalers to pharmaceutical retailers) not Canadian Pharma ($) $6,412k +1% reflected in Q1 2023 primary sales growth FeraMAX® +1% (BioSyent’s sales to wholesalers) • Expected
Slide 4: Sales, EBITDA and NIAT
Sales, EBITDA and NIAT Quarter (Q1) ended March 31, 2023 Sales 8,000 +22% +1% Canadian Pharma -5% (100%) International Pharma 7,000 -8% +35% (54%) Legacy 6,000 EBITDA / NIAT • +14% increase in selling & marketing 5,000 expenses Q1 2023 vs. Q1 2022 • Launch and pre-launch CAD (000's) 4,000 expenditur
Slide 5: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS Q1 2023 $1,175,246 $0.10 Q4 2022 $1,199,516 $0.09 $0.41 Q3 2022 $1,453,042 $0.12 Q2 2022 $1,217,883 $0.10 Q1 2022 $1,587,904 $0.13 Q4 2021 $1,877,804 $0.15 $0.49 Q3 2021 $1,721,320 $0.13 Q2 2021 $1,018,074 $0.08 5 | www.biosyent.com | TSXV: R
Slide 6: Most recommended iron supplement in Canada
▪ Most recommended iron supplement in Canada - pharmacists and physicians - 8 consecutive years(1) ▪ Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2022 Survey on OTC Counselling and Recomme
Slide 7: Product Innovation: A New Platform for FeraMAX
A New Platform for FeraMAX® Product Innovation ▪ FeraMAX® Pd platform introduced in October 2020 ▪ Patented delivery system based on Polydextrose Iron Complex (“PDIC”) ▪ Foundation for future product development ▪ Life Cycle Strategy – expanding leadership of FeraMAX® brand in Canada: “Iron health f
Slide 8: Introducing FeraMAX Pd Maintenance 45
Introducing FeraMAX® Pd Maintenance 45 ▪ Developed by BioSyent ▪ 3rd product incorporating PDIC ▪ Unique formulation: ▪ chewable ▪ pleasant taste ▪ 45 mg elemental iron ▪ supportive vitamins for iron health ▪ Designed to: ▪ prevent iron deficiency ▪ maintain healthy iron levels 8 | www.biosyent.com
Slide 9: Growth Drivers
Growth Drivers FeraMAX® Pd Platform – Life Cycle Strategy In development HRT agent for menopause therapy 1st pain relief formulation combining acetaminophen + ibuprofen in Canada New women’s health product – 2023 Launch New oncology supportive care product in-licensed December 2022 Acquisition and i
Slide 10: Cash Balance & Return on Equity (RoE)
Cash Balance & Return on Equity (“RoE”) 30,000 25% • Zero Debt 28,000 • TTM Mar 31, 2023 Cash from 21% 20% Operations of $4.0M 15% 26,000 26,844 26,249 • TTM Mar 31/23 NCIB share 15% 15% buybacks: $2.8M 24,000 CAD (000's) RoE % 24,024 10% • TTM Mar 31/23 Dividends of 22,000 $1.0M 20,000 5% • Mar 31/
Slide 11: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: Dividends $26.2M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders: • $0.04/share Dividend – Q4’22/Q1’23/Q2’23 = $ 1.5 M to d
Slide 12: Stock Information
Stock Information As at May 23, 2023 Exchange & Trading Symbol 0% TSXV: RX May 23, 2023 Closing Stock Price (CAD) $7.65 52 Week Hi/Low: $8.42 / $6.24 Issued Common Shares: 12,281,361 Treasury – RSU Shares in Trust (189,442) Outstanding Common Shares: 12,091,919 Options Outstanding 164,295 RSUs Outst
Slide 13: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 13 | www.biosyent.com | TSXV: RX
Slide 14: Thank You
THANK YOU 2476 Argentia Road, Suite 402 +1 905 206 0013 investors@biosyent.com www.biosyent.com Mississauga ON L5N 6M1 Canada 14 | www.biosyent.com | TSXV: RX